EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1923	544/235, 514/248	US-PGPUB; USPAT	OR	OFF	2006/08/30 15:25
L2	1361	544/235, 514/248	USPAT	OR	OFF	2006/08/30 15:25
L3	562	544/235, 514/248	US-PGPUB	OR	OFF	2006/08/30 15:25

Day : Wednesday
Date: 8/30/2006
Time: 15:22:06

PALM INTRANET

Inventor Information for 10/799389

Inventor Name	City	State/Country
ONO, MITSUNORI	LEXINGTON	MASSACHUSETTS
SUN, LIJUN	HARVARD	MASSACHUSETTS
XIA, ZHIQIANG	ACTON	MASSACHUSETTS
KOSTIK, ELENA	ARLINGTON	MASSACHUSETTS
KOYA, KEIZO	CHESTNUT HILL	MASSACHUSETTS
NAGAI, MASAZUMI	LEXINGTON	MASSACHUSETTS
WU, YAMING	LEXINGTON	MASSACHUSETTS

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity/Reexam | Foreign D

Search Another: Application# [ ] Search **or Patent#** [ ] Search

PCT / [ ] / [ ] Search **or PG PUBS #** [ ] Search

Attorney Docket # [ ] Search

Bar Code # [ ] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

chain nodes :
10 11 12 16
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
14
chain bonds :
8-16 10-11 11-12 11-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 6-9 10-11 11-12 11-14
exact bonds :
5-7 7-8 8-9 8-16
isolated ring systems :
containing 1 :

G1:O,S,N

G2:C,O,S,N,SO2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 14:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR





G1 O,S,N
G2 C,O,S,N,SO2

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:18:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 790 TO ITERATE

100.0% PROCESSED 790 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

Habte 08/30/2006

```
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        14114 TO    17486
PROJECTED ANSWERS:               6 TO      266

L2            6 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 14:18:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    16389 TO ITERATE

100.0% PROCESSED    16389 ITERATIONS                                75 ANSWERS
SEARCH TIME: 00.00.01

L3           75 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     166.94     167.15

FILE 'CAPLUS' ENTERED AT 14:18:35 ON 30 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 30 Aug 2006  VOL 145 ISS 10
FILE LAST UPDATED: 29 Aug 2006  (20060829/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4            6 L3

=> d ibib abs hitstr tot
```

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:534761 CAPLUS
DOCUMENT NUMBER: 145:28024
TITLE: Preparation of fused heterocyclic kinase inhibitors
INVENTOR(S): Borzilleri, Robert M.; Chen, Zhong; Huynh, Tram N.; Vaccaro, Wayne; Chen, Xiao-Tao; Kim, Kyoung S.; Cai, Zhen-Wei
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 141 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005288290	A1	20051229	US 2005-167043	20050624
WO 2006004636	A2	20060112	WO 2005-US22682	20050628
WO 2006004636	A3	20060526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2006004833	A2	20060112	WO 2005-US23099	20050628
WO 2006004833	A3	20060713		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2006004884	A2	20060112	WO 2005-US23198	20050628
WO 2006004884	A3	20060323		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: US 2004-583459P P 20040628
US 2004-612563P P 20040923

OTHER SOURCE(S): MARPAT 145:28024
GI


I


II


III

AB The title compds. I and II [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, CN, etc.; B = O, NR8, S, SO, SO2, CR9C10; V = NR11 or (CR47R48)p; W or X = C or N; Y = O, S, NR12; Z = CR13R14, (CR13R14)mNR15; m = 0-2; n = 0-4; p = 0-4, provided that if p = 0, R1 is not Ph; A = substituted pyrrolo[2,1-f][1,2,4]triazin-4-yl, pyrrolo[1,2-b]pyridazin-4-yl, pyrrolo[2,3-b]pyridin-4-yl, etc.; R3, R8, R11, R15 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl, heterocycloalkyl; R9, R10 = H, halo, alkyl, etc.; R12 = H, alkyl, CN, etc.; R13-R15, R47, R48 = H, halo, alkyl, etc.; and their pharmaceutically acceptable salts], useful as protein kinase inhibitors for treating cancer and other protein kinase mediated diseases, were prepared E.g., a multi-step synthesis of III, starting from Et 5-methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
carboxylate, was given. Compds. I and II inhibit the Met kinase with IC50 values between 0.01 to 100 μM. Pharmaceutical compns. comprising the compd. I or II alone or in combination with other antitumor agent are disclosed.

IT 888716-63-0P 888716-64-1P 888716-74-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer)

RN 888716-63-0 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-(pyrrolo[1,2-b]pyridazin-4-yloxy)phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 888716-64-1 CAPLUS

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-(pyrrolo[1,2-b]pyridazin-4-yloxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 888716-74-3 CAPLUS
CN Propanediamide, N-[3-fluoro-4-[(5-methylpyrrolo[1,2-b]pyridazin-4-yl)oxy]phenyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:534671 CAPLUS
DOCUMENT NUMBER: 145:28023
TITLE: Preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer
INVENTOR(S): Borzilleri, Robert M.; Chen, Zhong; Hunt, John T.; Huynh, Tram; Poss, Michael A.; Schroeder, Gretchen M.; Vaccaro, Wayne; Wong, Tai W.; Chen, Xiao-Tao; Kim, Kyoung S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 135 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006004006	A1	20060105	US 2005-167049	20050624
WO 2006004636	A2	20060112	WO 2005-US22682	20050628
WO 2006004636	A3	20060526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2006004833	A2	20060112	WO 2005-US23099	20050628
WO 2006004833	A3	20060713		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2006004884	A2	20060112	WO 2005-US23198	20050628
WO 2006004884	A3	20060323		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,				

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-583459P P 20040628
US 2004-612563P P 20040923

OTHER SOURCE(S): MARPAT 145:28023
GI



I II



III

AB The title compds. I and II [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, CN, etc.; B = O, NR8, S, SO, SO2, CR9C10; V = NR11 or (CR47R48)p; W or X = C or N; Y = O, S, NR12; Z = CR13R14, (CR13R14)mNR15; m = 0-2; n = 0-4; p = 0-4, provided that if p = 0, R1 is not Ph; A = substituted pyrrolo[2,1-f][1,2,4]triazin-4-yl, pyrrolo[1,2-b]pyridazin-4-yl, pyrrolo[2,3-b]pyridin-4-yl, etc.; R3, R8, R11, R15 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl, heterocycloalkyl; R9, R10 = H, halo, alkyl, etc.; R12 = H, alkyl, CN, etc.; R13-R15, R47, R48 = H, halo, alkyl, etc.; and their pharmaceutically acceptable salts], useful as protein kinase inhibitors for treating cancer and other protein kinase mediated diseases, were prepared E.g., a multi-step synthesis of III, starting from Et 5-methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

carboxylate, was given. Compds. I and II inhibit the Met kinase with IC50 values between 0.01 to 100 μM. Pharmaceutical compns. comprising the compd. I or II alone or in combination with other antitumor agent are disclosed.

IT 888716-63-0P 888716-64-1P 888716-74-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer)

RN 888716-63-0 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-(pyrrolo[1,2-b]pyridazin-4-yloxy)phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 888716-64-1 CAPLUS

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[pyrrolo[1,2-b]pyridazin-4-yloxy]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 888716-74-3 CAPLUS
CN Propanediamide, N-[3-fluoro-4-[(5-methylpyrrolo[1,2-b]pyridazin-4-yl)oxy]phenyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:31750 CAPLUS
DOCUMENT NUMBER: 144:128986
TITLE: Preparation of pyrrolopyridazine derivatives as inhibitors of phosphodiesterase-4 (PDE-IV) and production of tumor necrosis factor-α (TNF-α)
INVENTOR(S): Abe, Yoshito; Inoue, Makoto; Okumura, Mitsuaki; Ohne, Kazuhiko; Sato, Kentaro
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006004191	A1	20060112	WO 2005-JP12622	20050701
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: AU 2004-903690 A 20040705

OTHER SOURCE(S): MARPAT 144:128986
GI



I



II

AB Title compds. I [wherein R1 = H, (un)protected carboxy, (un)substituted alkyl, etc.; R2 = (un)substituted (cyclo)alkyl, aryl, etc.; R3 = H or alkyl; R2 and R3 may link together; R4 = (un)substituted (hetero)aryl, etc., and pharmaceutically acceptable salts or prodrugs thereof] were prepared as inhibitors of phosphodiesterase-4 (PDE-IV) and production of tumor necrosis factor-α (TNF-α). For instance, II, which showed inhibition for PDE-IV and on the production of TNF-α with IC50 values of < 1 μM and 64.0 nM, resp., was synthesized in multiple steps. Therefore, I and their pharmaceutical compns. are useful for the

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
of PDE-IV or TNF-α mediated diseases, such as asthma, COPD and hepatitis.
IT 873327-04-9P, tert-Butyl 4-[[7-ethyl-3-[[(4-methoxybenzyl)amino]carbonyl]-2-methylpyrrolo[1,2-b]pyridazin-4-yl]methyl]-1-piperidinecarboxylate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(inhibitor; preparation of pyrrolopyridazine deriv. as inhibitors of phosphodiesterase-4 and production of tumor necrosis factor-α)
RN 873327-04-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[7-ethyl-3-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-2-methylpyrrolo[1,2-b]pyridazin-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 873327-01-6P, tert-Butyl 4-[[[[4-(cyclohexylmethyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]carbonyl]amino]methyl]-1-piperidinecarboxylate 873327-03-8P, 3-[[4-Acetyl-1-piperazinyl]carbonyl]-4-(cyclohexylmethyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazine 873327-10-7P, 3-[[4-Acetyl-1-piperazinyl]carbonyl]-4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[1,2-b]pyridazine 873327-12-9P, tert-Butyl 4-[[[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[1,2-b]pyridazin-3-yl]carbonyl]amino]-1-piperidinecarboxylate 873327-13-0P, tert-Butyl 4-[[[[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl]pyrrolo[1,2-b]pyridazin-3-yl]carbonyl]amino]methyl]-1-piperidinecarboxylate 873327-37-8P, 4-[[1-Acetyl-4-piperidinyl]methyl]-7-ethyl-N-(4-methoxybenzyl)-2-methylpyrrolo[1,2-b]pyridazine-3-carboxamide 873327-48-1P, tert-Butyl 4-[[[4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[1,2-b]pyridazin-3-yl]carbonyl]amino]-1-piperidinecarboxylate 873327-49-2P, tert-Butyl 4-[[[7-ethyl-2-methyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]pyrrolo[1,2-b]pyridazin-3-yl]carbonyl]amino]methyl]-1-piperidinecarboxylate 873327-50-5P, tert-Butyl 4-[[[7-ethyl-2-methyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]pyrrolo[1,2-b]pyridazin-3-yl]carbonyl]amino]-1-piperidinecarboxylate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of pyrrolopyridazine derivs. as inhibitors of

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phosphodiesterase-4 and prodn. of tumor necrosis factor-α)
RN 873327-01-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[[4-(cyclohexylmethyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 873327-03-8 CAPLUS
CN Piperazine, 1-acetyl-4-[[4-(cyclohexylmethyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 873327-10-7 CAPLUS
CN Piperazine, 1-acetyl-4-[[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[1,2-b]pyridazin-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873327-48-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[1,2-b]pyridazin-3-yl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 873327-49-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[[7-ethyl-2-methyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]pyrrolo[1,2-b]pyridazin-3-yl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 873327-50-5 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873327-12-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[1,2-b]pyridazin-3-yl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 873327-13-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[1,2-b]pyridazin-3-yl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 873327-37-8 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-carboxamide, 4-[(1-acetyl-4-piperidinyl)methyl]-7-ethyl-N-[(4-methoxyphenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1-Piperidinecarboxylic acid, 4-[[[7-ethyl-2-methyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]pyrrolo[1,2-b]pyridazin-3-yl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 873326-82-0P, Ethyl 4-[[1-(tert-butoxycarbonyl)-4-piperidinyl]methyl]-7-ethyl-2-methylpyrrolo[1,2-b]pyridazine-3-carboxylate
873326-89-7P, 4-[[1-(tert-Butoxycarbonyl)-4-piperidinyl]methyl]-7-ethyl-2-methylpyrrolo[1,2-b]pyridazine-3-carboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolopyridazine derivs. as inhibitors of phosphodiesterase-4 and production of tumor necrosis factor-α)
RN 873326-82-0 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-carboxylic acid, 4-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]methyl]-7-ethyl-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 873326-89-7 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-carboxylic acid, 4-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]methyl]-7-ethyl-2-methyl- (9CI) (CA INDEX NAME)

own work

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:799444 CAPLUS
DOCUMENT NUMBER: 141:296005
TITLE: Preparation of fused pyrrole compounds as TNFα and/or PDE4 inhibitors for treatment of cancer, inflammatory disorders, and autoimmune diseases
INVENTOR(S): Ono, Mitsunori; Sun, Lijun; Xia, Zhi Qiang; Kostik, Elena; Koya, Keizo; Wu, Yaming; Nagai, Masazum
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082606	A2	20040930	WO 2004-US7469	20040311
WO 2004082606	A3	20050127		
WO 2004082606	C1	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004222387	A1	20040930	AU 2004-222387	20040311
CA 2517034	AA	20040930	CA 2004-2517034	20040311
EP 1601678	A2	20051207	EP 2004-719768	20040311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 2005014754	A1	20050120	US 2004-799389	20040312
PRIORITY APPLN. INFO.:			US 2003-454963P	P 20030313
			WO 2004-US7469	A 20040311

OTHER SOURCE(S): MARPAT 141:296005
GI

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I II

AB Title compds. I [wherein one of W1 and W2 = YC(=Z)NR1R2 and the other = XR3; V1-V4 = independently N, (un)substituted CH; or V1V2 or V3V4 = S, O, (un)substituted NH; or 2 adjacent V's form a fused aryl ring; X = bond, O, S, SO, SO2, CO, (un)substituted CH2, NH, CONH, NHCO; Y = O, S, SO, SO2, CO, (un)substituted CH2, NH, CONH, NHCO; Z = O, S, (un)substituted NOH, NH; R1, R2 = independently H, (un)substituted aliphatic group, heterocyclyl, aryl; or NR1R2 = heterocyclyl, heteroaryl; R3 = (un)substituted aryl, aliphatic; with provisos; and pharmaceutically acceptable salts and prodrugs thereof], such as indolizines, pyrrolo[1,2-b]pyridazines, and pyrrolo[2,1-b]thiazoles, were prepared as phosphodiesterase IV (PDE4) and/or tumor necrosis factor α (TNFα) inhibitors. For example, reaction of 2-bromo-4'-fluoroacetophenone with 3-methylpyridazine in the presence of DMF-Me2SO4 provided (4-fluorophenyl)(pyrrolo[1,2-b]pyridazin-7-yl)methanone, which was reduced to the benzyl derivative using BH3-THF. Sequential coupling with oxalyl chloride and 4-amino-3,5-dichloropyridine-N-oxide gave II (1.5% overall). The latter inhibited TNFα in human peripheral blood cells and PDE4 in U937 human monocytic cells with IC50 values of about 50 nM and about 5 nM, resp. II also demonstrated in vitro anticancer activity in human cancer cell line MDA435 with an IC50 value of about 1 μM. Thus, I and their pharmaceutical compns. are useful for the treatment or prevention of cancer, inflammatory disorders, autoimmune diseases, and other conditions involving PDE4 or elevated levels of cytokines.

IT 764723-23-1P, N-(3,5-Dichloro-1-oxopyridin-4-yl)-2-[7-(4-fluorobenzyl)pyrrolo[1,2-b]pyridazin-5-yl]-2-(oxo)acetamide 764723-27-5P, 2-[7-(4-Cyanobenzyl)pyrrolo[1,2-b]pyridazin-5-yl]-N-(3,5-dichloropyridin-4-yl)-2-(oxo)acetamide 764723-28-6P, 2-[7-(4-Methoxybenzyl)pyrrolo[1,2-b]pyridazin-5-yl]-2-oxo-N-(pyridin-4-yl)acetamide 764723-29-7P, 2-[7-(4-Chlorobenzyl)pyrrolo[1,2-b]pyridazin-5-yl]-N-(isoxazol-5-yl)-2-(oxo)acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cytokine inhibitor; prepn. of fused pyrrole compds. as TNFα and/or PDE4 inhibitors for treatment of cancer, inflammatory disorders, and autoimmune diseases)

RN 764723-23-1 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-5-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-7-[(4-fluorophenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 764723-27-5 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-5-acetamide, 7-[(4-cyanophenyl)methyl]-N-(3,5-dichloro-4-pyridinyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 764723-28-6 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-5-acetamide, 7-[(4-methoxyphenyl)methyl]-α-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 764723-29-7 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-5-acetamide, 7-[(4-chlorophenyl)methyl]-N-5-isoxazolyl-α-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:606471 CAPLUS
DOCUMENT NUMBER: 141:157123
TITLE: Preparation of pyrrolopyridazines as inhibitors of phosphodiesterase IV (PDE IV) and production of tumor necrosis factor-α (TNF-α)
INVENTOR(S): Abe, Yoshito; Inoue, Makoto; Mizutani, Tsuyoshi; Sawada, Kozo; Ohne, Kazuhiko; Okumura, Mitsuaki; Sawada, Yuki; Imamura, Kenichiro
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 360 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063197	A1	20040729	WO 2003-JP17091	20031226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2513081	AA	20040729	CA 2003-2513081	20031226
AU 2003294183	A1	20040810	AU 2003-294183	20031226
EP 1581535	A1	20051005	EP 2003-789642	20031226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017358	A	20051213	BR 2003-17358	20031226
CN 1759117	A	20060412	CN 2003-80110135	20031226
JP 2006515597	T2	20060601	JP 2004-566309	20031226
US 2005075342	A1	20050407	US 2003-747079	20031230
NO 2005003748	A	20051007	NO 2005-3748	20050804
PRIORITY APPLN. INFO.:			AU 2003-900189 A	20030109
			AU 2003-903628 A	20030714
			WO 2003-JP17091 W	20031226

OTHER SOURCE(S): MARPAT 141:157123
GI

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [wherein R1 = (un)protected CO2H, CONH2 and derivs., OH and lower alkoxy, mono/di/cyclo(lower)alkylamino, trihalo(lower)alkyl, (un)substituted lower alkyl, aryl, heterocyclyl; R2 = R7, or -(A1)p-XA2A7; p = 0-1; A1 = ethylene, HC:CH; A2 = (CH2)n, (HC:CH)m; n = 1-6; m = 1-3; X = a single bond, O, NH and derivs., C(:O), hydroxyalkylne, etc.; R7 = H, (un)substituted aryl, heterocyclyl, CO2H and derivs., acyl, CN, NH2 and derivs., OH, aryloxy, acyloxy; R1R2 = (un)substituted lower alk(en)ylene, optionally interrupted by nH2, or sulfonyl, and optionally fused with benzene; R3 = (un)substituted aryl, heterocyclyl; R4 = H, halo, CN, carbamoyl, acyl, thiocyanate, lower alkylthio, lower alk(en)yl, hydroxy(lower)alkyl, trihalo(lower)alkyl; and their pharmaceutically acceptable salts or prodrugs] were prepared as inhibitors of phosphodiesterase IV (PDE IV) and production of tumor necrosis factor-α (TNF-α). Thus, reacting Et 7-(4-cyanobenzoyl)-8-oxononanoate (preparation given) with 2-ethyl-1H-pyrrol-1-amine in toluene in the presence of p-TSA at reflux, followed ester hydrolysis in the presence of KOH/MeOH gave pyrrolopyridazine II and its 4-(aminocarbonyl)phenyl derivative Pyrrolopyridazine II displayed an IC50 < 1 μM for PDE IV inhibition. II gave an IC50 < 100 μM for the inhibition of TNF-α production I are useful for treating asthma, COPD, fibrosis, hepatitis, Alzheimer's diseases, etc.

IT 728011-71-0P, Ethyl 7-[4-[4-[[[(benzyloxy)carbonyl]amino]sulfonyl]phenyl]-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]heptanoate 728015-23-4P, Ethyl 2-(2-amino-2-oxoethyl)-4-(4-cyanophenyl)-7-ethylpyrrolo[1,2-b]pyridazine-3-carboxylate 728015-80-3P, tert-Butyl [4-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]butyl]carbamate 728017-66-1P, Ethyl 5-[4-[5-[(tert-butoxycarbonyl)amino]-3-pyridinyl]-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]pentanoate

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(phosphodiesterase IV inhibitor; prepn. of pyrrolopyridazines as inhibitors of phosphodiesterase IV and prodn. of tumor necrosis factor-α (TNF-α))

RN 728011-71-0 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-heptanoic acid, 7-ethyl-2-methyl-4-[4-[[[(phenylmethoxy)carbonyl]amino]sulfonyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 728015-23-4 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-carboxylic acid, 2-(2-amino-2-oxoethyl)-4-(4-cyanophenyl)-7-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 728015-80-3 CAPLUS
CN Carbamic acid, [4-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728017-66-1 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 4-[5-[[(1,1-dimethylethoxy)carbonyl]amino]-3-pyridinyl]-7-ethyl-2-methyl-, ethyl ester
(9CI) (CA INDEX NAME)



IT 728015-56-3P, 2-[[3-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]propanoyl]amino]ethanesulfonic acid 728015-59-6P 728015-68-7P 728015-72-3P,
N-[5-[4-(3-Cyanophenyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]pentanoyl]methanesulfonamide 728016-38-4P,
5-[4-(3-Cyanophenyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]-N-(2-pyridinyl)pentanamide 728016-40-8P, 5-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]-N-(2-pyridinyl)pentanamide 728016-42-0P, N-[5-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]pentanoyl]methanesulfonamide 728016-44-2P,

5-[4-(2-Chloro-4-pyridinyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]-N-(2-pyridinyl)pentanamide 728016-46-4P, N-[5-[4-(5-Bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]pentanoyl]methanesulfonamide 728016-66-8P,
5-[4-(3-Cyanophenyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]-N-methylpentanamide 728016-68-0P, 4-(3-Chlorophenyl)-7-ethyl-3-[5-(4-morpholinyl)-5-oxopentyl]-2-phenylpyrrolo[1,2-b]pyridazine 728016-70-4P, 5-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]-N-methylpentanamide 728016-72-6P,

5-[4-(2-Chloro-4-pyridinyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]-N-methylpentanamide 728016-74-8P, 3-[7-Ethyl-3-[5-(4-morpholinyl)-5-oxopentyl]-2-phenylpyrrolo[1,2-b]pyridazin-4-yl]benzonitrile 728016-76-0P, 3-[7-Ethyl-2-methyl-3-[5-(4-morpholinyl)-5-oxopentyl]pyrrolo[1,2-b]pyridazin-4-yl]benzonitrile 728016-78-2P, 5-[4-(3-Cyanophenyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]pentanamide 728017-85-4P, Ethyl 5-[7-ethyl-4-(5-methyl-3-pyridinyl)-2-[[2-(4-morpholinyl)-2-oxoethoxy]methyl]pyrrolo[1,2-b]pyridazin-3-yl]pentanoate 728017-86-5P, Ethyl 5-[7-ethyl-2-[[2-(methylamino)-2-oxoethoxy]methyl]-4-(5-methyl-3-pyridinyl)pyrrolo[1,2-b]pyridazin-3-yl]pentanoate 728017-90-1P, Ethyl 5-[2-[(acetylamino)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[1,2-b]pyridazin-3-yl]pentanoate 728017-94-5P, Ethyl 5-[7-ethyl-2-[[(methoxycarbonyl)amino]methyl]-4-(5-methyl-3-pyridinyl)pyrrolo[1,2-b]pyridazin-3-yl]pentanoate 728018-21-1P, 5-[7-Ethyl-4-(5-methyl-3-pyridinyl)-2-[[2-(4-morpholinyl)-2-oxoethoxy]methyl]pyrrolo[1,2-b]pyridazin-3-yl]pentanoic acid 728018-22-2P, 5-[7-Ethyl-2-[[2-(methylamino)-2-oxoethoxy]methyl]-4-(5-methyl-3-pyridinyl)pyrrolo[1,2-b]pyridazin-3-yl]pentanoic acid 728018-30-2P, 5-[2-[(Acetylamino)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[1,2-b]pyridazin-3-yl]pentanoic acid 728018-34-6P, 5-[7-Ethyl-2-[[(methoxycarbonyl)amino]methyl]-4-(5-methyl-3-pyridinyl)pyrrolo[1,2-b]pyridazin-3-yl]pentanoic acid 728018-46-0P, 4-(5-Bromo-3-pyridinyl)-7-ethyl-2-methyl-3-[3-(4-morpholinyl)-3-oxopropyl]pyrrolo[1,2-b]pyridazine 728018-47-1P,

3-[4-(5-Bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]-N-methylpropanamide 728018-48-2P, N-[3-[4-(5-Bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]propanoyl]methanesulfonamide 728018-49-3P, 2-[[3-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]propanoyl](methyl)amino]ethanesulfonic acid 728020-31-3P, 5-[4-(5-Bromo-3-pyridinyl)-7-ethyl-2-[[[(4-morpholinyl)carbonyl]oxy]methyl]pyrrolo[1,2-b]pyridazin-3-yl]pentanoic acid 728020-32-4P, 5-[4-(5-Bromo-3-pyridinyl)-2-[[[(dimethylamino)carbonyl]oxy]methyl]-7-ethylpyrrolo[1,2-b]pyridazin-3-yl]pentanoic acid 728020-33-5P, 5-[4-(5-Bromo-3-pyridinyl)-7-ethyl-2-[[[(1-pyrrolidinyl)carbonyl]oxy]methyl]pyrrolo[1,2-b]pyridazin-3-yl]pentanoic acid 728020-34-6P, 5-[4-(5-Bromo-3-pyridinyl)-7-ethyl-2-[[[(methyl(phenyl)amino]carbonyl]oxy]methyl]pyrrolo[1,2-b]pyridazin-3-yl]pentanoic acid 728020-35-7P,

4-[4-(5-Bromo-3-pyridinyl)-7-ethyl-2-[[[(4-morpholinyl)carbonyl]oxy]methyl]pyrrolo[1,2-b]pyridazin-3-yl]butanoic acid 728020-36-8P,
4-[4-(5-Bromo-3-pyridinyl)-2-[[[(dimethylamino)carbonyl]oxy]methyl]-7-ethylpyrrolo[1,2-b]pyridazin-3-yl]butanoic acid 728020-37-9P,
3-[4-(5-Bromo-3-pyridinyl)-2-[[[(dimethylamino)carbonyl]oxy]methyl]-7-ethylpyrrolo[1,2-b]pyridazin-3-yl]propanoic acid 728020-57-3P,
5-[2-[[2-(Benzylamino)-2-oxoethoxy]methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[1,2-b]pyridazin-3-yl]pentanoic acid 728020-98-2P 728021-11-2P 728021-13-4P, N-(2-Aminoethyl)-3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[1,2-b]pyridazin-3-yl]propanamide 728021-52-1P, 3-[4-(5-Bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[1,2-b]pyridazin-3-yl]-N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]propanamide 728021-53-2P, tert-Butyl [2-[[3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[1,2-b]pyridazin-3-yl]propanoyl]amino]ethyl]carbamate 728021-54-3P,

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Ethyl 5-[2-[[2-(benzylamino)-2-oxoethoxy]methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[1,2-b]pyridazin-3-yl]pentanoate 728021-59-8P,
tert-Butyl [2-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]ethyl]carbamate 728021-66-7P
728021-67-8P, Ethyl 5-[4-(5-bromo-3-pyridinyl)-2-[[[(dimethylamino)carbonyl]oxy]methyl]-7-ethylpyrrolo[1,2-b]pyridazin-3-yl]pentanoate 728021-68-9P, [4-(5-Bromo-3-pyridinyl)-3-(5-ethoxy-5-oxopentyl)-7-ethylpyrrolo[1,2-b]pyridazin-2-yl]methyl 1-pyrrolidinecarboxylate 728021-69-0P, Ethyl

5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-[[[(methyl(phenyl)amino]carbonyl]oxy]methyl]pyrrolo[1,2-b]pyridazin-3-yl]pentanoate 728021-70-3P,
[4-(5-Bromo-3-pyridinyl)-3-(4-ethoxy-4-oxobutyl)-7-ethylpyrrolo[1,2-b]pyridazin-2-yl]methyl 4-morpholinecarboxylate 728021-72-5P,
Ethyl
4-[4-(5-bromo-3-pyridinyl)-2-[[[(dimethylamino)carbonyl]oxy]methyl]-7-ethylpyrrolo[1,2-b]pyridazin-3-yl]butanoate 728021-74-7P,
Ethyl
3-[4-(5-bromo-3-pyridinyl)-2-[[[(dimethylamino)carbonyl]oxy]methyl]-7-ethylpyrrolo[1,2-b]pyridazin-3-yl]propanoate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phosphodiesterase IV inhibitor; prepn. of pyrrolopyridazines as inhibitors of phosphodiesterase IV and prodn. of tumor necrosis factor-α (TNF-α))
RN 728015-56-3 CAPLUS
CN Ethanesulfonic acid, 2-[[3-(4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 728015-59-6 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-propanamide, 4-(3-chlorophenyl)-7-ethyl-2-phenyl-N-[2,3,4,6-tetrakis-O-(2,2-dimethyl-1-oxopropyl)-β-D-galactopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728015-68-7 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-propanamide, 4-(3-chlorophenyl)-7-ethyl-N-β-D-galactopyranosyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728015-72-3 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanamide, 4-(3-cyanophenyl)-7-ethyl-2-methyl-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 728016-38-4 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanamide, 4-(3-cyanophenyl)-7-ethyl-2-phenyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728016-40-8 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanamide, 4-(3-chlorophenyl)-7-ethyl-2-phenyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 728016-42-0 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanamide, 4-(3-chlorophenyl)-7-ethyl-N-(methylsulfonyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 728016-44-2 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanamide, 4-(2-chloro-4-pyridinyl)-7-ethyl-2-phenyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728016-46-4 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanamide, 4-(5-bromo-3-pyridinyl)-7-ethyl-2-methyl-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 728016-66-8 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanamide, 4-(3-cyanophenyl)-7-ethyl-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 728016-68-0 CAPLUS
CN Morpholine, 4-[5-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]-1-oxopentyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728016-70-4 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanamide, 4-(3-chlorophenyl)-7-ethyl-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 728016-72-6 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanamide, 4-(2-chloro-4-pyridinyl)-7-ethyl-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 728016-74-8 CAPLUS
CN Morpholine, 4-[5-[4-(3-cyanophenyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]-1-oxopentyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728016-76-0 CAPLUS
CN Morpholine, 4-[5-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]-1-oxopentyl]- (9CI) (CA INDEX NAME)



RN 728016-78-2 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanamide, 4-(3-cyanophenyl)-7-ethyl-2-methyl- (9CI) (CA INDEX NAME)



RN 728017-85-4 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 7-ethyl-4-(5-methyl-3-pyridinyl)-2-[[2-(4-morpholinyl)-2-oxoethoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728017-86-5 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 7-ethyl-2-[[2-(methylamino)-2-oxoethoxy]methyl]-4-(5-methyl-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 728017-90-1 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 2-[(acetylamino)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 728017-94-5 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 7-ethyl-2-[[(methoxycarbonyl)amino]methyl]-4-(5-methyl-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728018-34-6 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 7-ethyl-2-[[(methoxycarbonyl)amino]methyl]-4-(5-methyl-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 728018-46-0 CAPLUS
CN Morpholine, 4-[3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 728018-47-1 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-propanamide, 4-(5-bromo-3-pyridinyl)-7-ethyl-N,2-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728018-21-1 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 7-ethyl-4-(5-methyl-3-pyridinyl)-2-[[2-(4-morpholinyl)-2-oxoethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 728018-22-2 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 7-ethyl-2-[[2-(methylamino)-2-oxoethoxy]methyl]-4-(5-methyl-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 728018-30-2 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 2-[(acetylamino)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728018-48-2 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-propanamide, 4-(5-bromo-3-pyridinyl)-7-ethyl-2-methyl-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 728018-49-3 CAPLUS
CN Ethanesulfonic acid, 2-[[3-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[1,2-b]pyridazin-3-yl]-1-oxopropyl]methylamino]- (9CI) (CA INDEX NAME)



RN 728020-31-3 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 4-(5-bromo-3-pyridinyl)-7-ethyl-2-[[[(4-morpholinylcarbonyl)oxy]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728020-32-4 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 4-(5-bromo-3-pyridinyl)-2-[[[(dimethylamino)carbonyl]oxy]methyl]-7-ethyl- (9CI) (CA INDEX NAME)



RN 728020-33-5 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 4-(5-bromo-3-pyridinyl)-7-ethyl-2-[[[(1-pyrrolidinylcarbonyl)oxy]methyl]- (9CI) (CA INDEX NAME)



RN 728020-34-6 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 4-(5-bromo-3-pyridinyl)-7-ethyl-2-[[[(methylphenylamino)carbonyl]oxy]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728020-35-7 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-butanoic acid, 4-(5-bromo-3-pyridinyl)-7-ethyl-2-[[(4-morpholinylcarbonyl)oxy]methyl]- (9CI) (CA INDEX NAME)



RN 728020-36-8 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-butanoic acid, 4-(5-bromo-3-pyridinyl)-2-[[[(dimethylamino)carbonyl]oxy]methyl]-7-ethyl- (9CI) (CA INDEX NAME)



RN 728020-37-9 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-propanoic acid, 4-(5-bromo-3-pyridinyl)-2-[[[(dimethylamino)carbonyl]oxy]methyl]-7-ethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728020-57-3 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 7-ethyl-4-(5-methyl-3-pyridinyl)-2-[[2-oxo-2-[(phenylmethyl)amino]ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 728020-98-2 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-propanamide, 4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)-N-[2,3,4,6-tetrakis-O-(2,2-dimethyl-1-oxopropyl)-β-D-galactopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728021-11-2 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-propanamide, 4-(5-bromo-3-pyridinyl)-7-ethyl-N-β-D-galactopyranosyl-2-(methoxymethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 728021-13-4 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-propanamide, N-(2-aminoethyl)-4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 728021-52-1 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-propanamide, 4-(5-bromo-3-pyridinyl)-7-ethyl-N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 728021-53-2 CAPLUS
CN Carbamic acid, [2-[[3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[1,2-b]pyridazin-3-yl]-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728021-54-3 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 7-ethyl-4-(5-methyl-3-pyridinyl)-2-[[2-oxo-2-[(phenylmethyl)amino]ethoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 728021-59-8 CAPLUS
CN Carbamic acid, [2-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[1,2-b]pyridazin-3-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 728021-66-7 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 4-(5-bromo-3-pyridinyl)-7-ethyl-2-[[(4-morpholinylcarbonyl)oxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 728021-67-8 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 4-(5-bromo-3-pyridinyl)-2-[[[(dimethylamino)carbonyl]oxy]methyl]-7-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 728021-68-9 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 4-(5-bromo-3-pyridinyl)-7-ethyl-2-[[(1-pyrrolidinylcarbonyl)oxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 728021-69-0 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-pentanoic acid, 4-(5-bromo-3-pyridinyl)-7-ethyl-2-[[[(methylphenylamino)carbonyl]oxy]methyl]-, ethyl ester (9CI) (CA

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
INDEX NAME)



RN 728021-70-3 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-butanoic acid, 4-(5-bromo-3-pyridinyl)-7-ethyl-2-[[(4-morpholinylcarbonyl)oxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 728021-72-5 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-butanoic acid, 4-(5-bromo-3-pyridinyl)-2-[[[(dimethylamino)carbonyl]oxy]methyl]-7-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 728021-74-7 CAPLUS
CN Pyrrolo[1,2-b]pyridazine-3-propanoic acid, 4-(5-bromo-3-pyridinyl)-2-[[[(dimethylamino)carbonyl]oxy]methyl]-7-ethyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:151782 CAPLUS
DOCUMENT NUMBER: 116:151782
TITLE: Preparation of pyrrolopyridazines as hydroxymethylglutaryl (HMG) CoA reductase inhibitors
INVENTOR(S): Matsuo, Masaaki; Manabe, Takashi; Okumura, Hiroyuki; Matsuda, Hiroshi; Fujii, Naoaki
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9118903	A1	19911212	WO 1991-JP678	19910522
W: AU, CA, FI, HU, JP, KR, NO, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9178918	A1	19911231	AU 1991-78918	19910522
JP 06501918	T2	19940303	JP 1991-509210	19910522
CN 1056690	A	19911204	CN 1991-102784	19910524
PRIORITY APPLN. INFO.:			GB 1990-11837 A	19900525
			GB 1990-19173 A	19900903
			WO 1991-JP678 A	19910522

OTHER SOURCE(S): MARPAT 116:151782
GI





AB Title compds. I [R1, R2 = (C3-8 cycloalkyl) C1-6 alkyl, C3-8 cycloalkyl, (substituted) aryl; R3, R4 = H, (aryl)C1-6 alkyl, halo, (substituted)

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
aryl(thio), (protected) carboxy, acyl, (substituted) N-heterocyclyl, etc.; Y = CH:CH, CH2CH2; Z = CHOHCH2CHOHCH2R5, Q; R5 = (protected) carboxy, R8 = (protected) OH] were prepd. as inhibitors of HMG CoA reductase. Thus, MeCOCH2CO2Me was condensed with (E)-3-[2-(4-fluorophenyl)-4-isopropylpyrrolo[1,2-b]pyridazin-3-yl]acrylaldehyde (prepn. given) in the presence of NaH to give (E)-RCH:CHCHOHCH2COCH2CO2Me [R = 2-(4-fluorophenyl)-4-isopropylpyrrolo[1,2-b]pyridazin-3-yl]. This was reduced by Et2BOMe and NaBH4 to give (±)-erythro-(E)-RCH:CHCHOHCH2CHOHCH2CO2Me. Sapon. of the latter by NaOH gave title compd.
II which had IC50 of 0.009 μg/mL in vitro against HMG CoA reductase.
IT 139506-73-3P 139563-30-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as hydroxymethylglutaryl CoA reductase inhibitor)
RN 139506-73-3 CAPLUS
CN 6-Heptenamide, 7-[2-(4-fluorophenyl)-4-(1-methylethyl)pyrrolo[1,2-b]pyridazin-3-yl]-3,5-dihydroxy-N-(1-phenylethyl)-, [3R-[1(S*),3R*,5S*,6E]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 139563-30-7 CAPLUS
CN 6-Heptenamide, 7-[2-(4-fluorophenyl)-4-(1-methylethyl)pyrrolo[1,2-b]pyridazin-3-yl]-3,5-dihydroxy-N-(1-phenylethyl)-, [3R-[1(R*),3R*,5S*,6E]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.